AXSOME THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
AXSOME THERAPEUTICS, INC. (AXSM) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$13.67 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-08.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-08-08
- AXSOME THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$6.28M.
- AXSOME THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$7.39M, a 187.95% decline year-over-year.
- AXSOME THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $2.35M, a 14.02% decline year-over-year.
- AXSOME THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$6.32M.
- AXSOME THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$2.60M.
- AXSOME THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$11.42M, a 125.14% decline from fiscal 2015.
- AXSOME THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $45.42M, a 8469.97% increase from fiscal 2014.
- AXSOME THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $529.97K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$6.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$13.67M 10-Q · filed 2018-08-08 | -$11.32M derived: sum of 3 quarters · filed 2018-08-08 | -$17.64M derived: sum of 4 quarters · filed 2018-08-08 |
| 2018-03-31 | -$7.39M 10-Q · filed 2018-05-08 | -$5.04M derived: sum of 2 quarters · filed 2018-05-08 | -$11.36M derived: sum of 3 quarters · filed 2018-05-08 | -$18.39M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$3.97M derived: sum of 2 quarters · filed 2018-03-07 | -$11.00M derived: sum of 3 quarters · filed 2018-08-08 | -$2.60M 10-K · filed 2018-03-07 |
| 2017-09-30 | -$6.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$13.35M derived: sum of 2 quarters · filed 2018-08-08 | -$4.95M 10-Q · filed 2017-11-08 | -$2.21M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-06-30 | -$7.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $1.38M 10-Q · filed 2018-08-08 | $4.11M derived: sum of 3 quarters · filed 2018-08-08 | -$757.30K derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | $8.40M 10-Q · filed 2018-05-08 | $11.13M derived: sum of 2 quarters · filed 2018-05-08 | $6.27M derived: sum of 3 quarters · filed 2018-05-08 | $941.63K derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$2.13M derived: sum of 2 quarters · filed 2018-03-07 | -$7.46M derived: sum of 3 quarters · filed 2018-03-07 | -$11.42M 10-K · filed 2018-03-07 |
| 2016-09-30 | -$4.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$10.19M derived: sum of 2 quarters · filed 2017-11-08 | -$14.15M 10-Q · filed 2017-11-08 | $29.27M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$5.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$9.28M 10-Q · filed 2017-08-09 | $34.13M derived: sum of 3 quarters · filed 2018-03-07 | $32.34M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | -$3.96M 10-Q · filed 2017-05-09 | $39.46M derived: sum of 2 quarters · filed 2018-03-07 | $37.66M derived: sum of 3 quarters · filed 2018-03-07 | $42.39M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $43.42M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $41.62M derived: sum of 2 quarters · filed 2018-03-07 | $46.35M derived: sum of 3 quarters · filed 2018-03-07 | $45.42M 10-K · filed 2018-03-07 |
| 2015-09-30 | -$1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $2.93M derived: sum of 2 quarters · filed 2016-11-14 | $2.00M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $4.72M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2016-08-09 | $3.80M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$927.38K 10-Q/A · filed 2016-08-09 | |||
| 2014-12-31 | $529.97K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |